# Nanoparticles‐Mediated Modulation of TRP Channels: Advances and Therapeutic Potential

**Authors:** Karina A. Foster, Noy Midler, Ori Shine, Dekel Rosenfeld

PMC · DOI: 10.1002/wnan.70058 · Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology · 2026-02-27

## TL;DR

This review explores how nanoparticles can control TRP ion channels, offering new ways to develop minimally invasive therapies for various diseases.

## Contribution

The paper systematically reviews the therapeutic potential of nanoparticle-mediated modulation of TRP channels.

## Key findings

- Nanoparticles can activate TRP channels using optical, electrical, and magnetic signals.
- TRP channels are key targets for controlling cell signaling in physiological and pathological contexts.
- Advances in nanotechnology can lead to precise and non-invasive therapeutic strategies.

## Abstract

Nanoparticles have emerged as promising tools for targeting and activating ion channels that serve as transducers for external signals. Their nanoscale dimensions enable targeted activation of ion channels at the cellular or subcellular level, offering unprecedented opportunities to control biological cell signaling. Recent works have demonstrated nanoparticle‐mediated stimulation based on optical, electrical, and magnetic external signals, highlighting their potential to serve as minimally invasive therapeutics. In addition, there is an increasing need to identify relevant ion channels and their physiological role in advancing emerging nanotechnologies. The transient receptor potential (TRP) family, including prominent members such as the TRPV (vanilloid), TRPM (Melastatin), and TRPA (ankyrin), plays critical roles in physiological functions, such as temperature sensation, pain perception, and mechanical stimulus detection, and can be controlled via nanoparticle signaling. This review highlights the properties and roles of dominant TRP family members in different organs and positions them as relevant targets for novel technologies. Leveraging the knowledge of nanoparticle properties with recent advances in pharmacology and disease treatments that target TRP family members will enhance the development of novel nano‐biotechnologies to control cell signaling.

Nanoparticle‐mediated modulation of TRP channels, highlighting the interplay between external stimuli, tailored nanomaterials, and TRP channel activation across a range of physiological contexts. This review examines the roles of TRP channels in cellular signaling and disease, providing insights into how advances in nanotechnology can facilitate precise, minimally invasive therapeutic strategies. Created in https://BioRender.com.

## Linked entities

- **Proteins:** TYRP1 (tyrosinase related protein 1), iav (inactive), Trpm (Transient receptor potential cation channel, subfamily M), TPSG1 (tryptase gamma 1)

## Full-text entities

- **Genes:** TRPV4 (transient receptor potential cation channel subfamily V member 4) [NCBI Gene 59341] {aka BCYM3, CMT2C, HMSN2C, OTRPC4, SMAL, SPSMA}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, SNCB (synuclein beta) [NCBI Gene 6620], INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, TRPV2 (transient receptor potential cation channel subfamily V member 2) [NCBI Gene 51393] {aka VRL, VRL-1, VRL1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, TRPM3 (transient receptor potential cation channel subfamily M member 3) [NCBI Gene 80036] {aka CTRCT50, GON-2, LTRPC3, MLSN2, NEDFSS}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, TrpA1 (Transient receptor potential cation channel A1) [NCBI Gene 39015] {aka ANKTM1, Anktm1, CG5751, CG5761, CT18073, DmTRPA1}, TPSG1 (tryptase gamma 1) [NCBI Gene 25823] {aka PRSS31, TMT, trpA}
- **Diseases:** obesity (MESH:D009765), knee pain (MESH:D046788), AKI (MESH:D058186), PTSD (MESH:D013313), hyperthermia (MESH:D005334), osteoarthritis (MESH:D010003), ischemia (MESH:D007511), neurological disorders (MESH:D009461), Visceral Disorders (MESH:D007418), itch (MESH:D011537), pain-related disorders (MESH:D013001), cardiac fibrosis (MESH:D005355), Conditions (MESH:D020763), Inflammatory Diseases (MESH:D007249), injury (MESH:D014947), Neurodegenerative Disorders (MESH:D019636), PD (MESH:D010300), Respiratory Diseases (MESH:D012140), Pain (MESH:D010146), cancer (MESH:D009369), endothelial dysfunction (MESH:D014652), neurological, inflammatory, and (MESH:D018746), AD (MESH:D000544), Psychiatric Disorders (MESH:D001523), neuroinflammation (MESH:D000090862), anxiety (MESH:D001007), chronic kidney disease (MESH:D051436), renal disorders (MESH:D007674), IBD (MESH:D015212), Neuropathic pain (MESH:D009437), thermal hypersensitivity (MESH:D004342), atopic dermatitis (MESH:D003876), mechanical hyperalgesia (MESH:D006930), reperfusion injury (MESH:D015427), epilepsy (MESH:D004827), RA (MESH:D001172), anemia (MESH:D000740), atherosclerotic lesion (MESH:D050197), nerve injury (MESH:D000080902), hypertension (MESH:D006973), Metabolic and Endocrine System Disorders (MESH:D004700), synovitis (MESH:D013585), ischemic injury (MESH:D017202), Cardiovascular Diseases (MESH:D002318), insulin resistance (MESH:D007333), skeletal dysplasia (MESH:C535858), Toxicity (MESH:D064420), cough (MESH:D003371)
- **Chemicals:** water (MESH:D014867), cinnamaldehyde (MESH:C012843), 4-hydroxy-2-nonenal (MESH:C027576), Ag (MESH:D012834), polydopamine (MESH:C568283), SZV-1287 (MESH:C000613315), iron oxide (MESH:C000499), aldehydes (MESH:D000447), resiniferatoxin (MESH:C024353), cholesterol (MESH:D002784), Au (MESH:D006046), isosakuranetin (MESH:C538973), 5,6-epoxyeicosatrienoic acid (MESH:C040776), capsazepine (MESH:C071423), acetaminophen (MESH:D000082), magnetite (MESH:D052203), 4alpha-PDD (MESH:C008876), AITC (MESH:C004471), phosphatidylinositol 4,5-bisphosphate (MESH:D019269), cortisol (MESH:D006854), HC-030031 (MESH:C552888), polymers (MESH:D011108), triglyceride (MESH:D014280), Capsaicin (MESH:D002211), ATP (MESH:D000255), ruthenium red (MESH:D012430), lipid (MESH:D008055), MnFe2O4 (MESH:C551151), pregnenolone sulfate (MESH:C018370), dopamine (MESH:D004298), PLGA (MESH:D000077182), allicin (MESH:C006452), calcium (MESH:D002118), lanthanide (MESH:D028581), chloroquine (MESH:D002738), magnesium (MESH:D008274), RN-1747 (MESH:C544742), glucose (MESH:D005947), serotonin (MESH:D012701), bile acids (MESH:D001647), CIM-0216 (MESH:C000623366), AuNR (-), hydrogen peroxide (MESH:D006861), GSK1016790A (MESH:C530602), Na+ (MESH:D012964), K+ (MESH:D011188), SiO2 (MESH:D012822), primidone (MESH:D011324), catecholamines (MESH:D002395), acrolein (MESH:D000171), A-967079 (MESH:C560402), baclofen (MESH:D001418)
- **Species:** Serpentes (snakes, infraorder) [taxon 8570], Drosophila melanogaster (fruit fly, species) [taxon 7227], Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989]
- **Mutations:** C-34 C, C-10 C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12948659/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12948659/full.md

## References

147 references — full list in the complete paper: https://tomesphere.com/paper/PMC12948659/full.md

---
Source: https://tomesphere.com/paper/PMC12948659